Stockreport

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights [Financial Post (Toronto, Ontario, Canada)]

ProMIS Neurosciences Inc.  (PMN) 
PDF Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 CAMBRIDGE, Massachusetts and TORONTO, [Read more]